# Catherine Boule

> Catherine Boule is a seed investor at Karista (Paris) backing Health Care and Biotechnology. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Karista](https://shizune.co/investors/profile/karista)
- Location: Paris, France
- Total investments: 19
- Last investment: Sep 2022
- Lead investor: 16%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/catherine-boule-5039128

Catherine Boule is a seed investor at Karista in Paris focused on Health Care and Biotechnology. Catherine Boule - Managing Partner @ Karista

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 37% |
| Biotechnology | 7 | 37% |
| Medical | 6 | 32% |
| Medical Device | 5 | 26% |
| Therapeutics | 3 | 16% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 53% |
| Series A | 3 | 16% |
| Funding Round | 2 | 11% |
| Series B | 1 | 5% |
| Series C | 1 | 5% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Incepto Medical | Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $27.1M | Venture - Series Unknown | Sep 19, 2022 |  |
| Ludocare | Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life. | $4.4M | Seed | Jul 04, 2022 |  |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $7.7M | Series B | Nov 06, 2019 |  |
| Incepto Medical | Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $6.1M | Seed | Sep 24, 2019 |  |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $16.8M | Series B | Oct 17, 2018 |  |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. |  | Seed | Feb 07, 2017 |  |
| TISSIUM | TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $8.8M | Series A | Dec 09, 2013 |  |
| VitamFero | Incorporated in late 2005, VitamFero SA is a privately held biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexe parasites such as:- Toxoplasma gondii (toxoplasmosis agent)- Neospora caninum(neosporosis agent)- Cryptosporidium parvum (cryptosporidiosis agent).With headquarters in Evry (France) and laboratories in Tours (France), VitamFero is involved first in veterinary healthcare. |  | Seed | Feb 21, 2011 |  |
| Nanobiotix | Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnosticof cancer. | $7.7M | Series C | May 05, 2010 |  |
| e(ye)BRAIN | e(ye)BRAIN is a medical company that manufactures and distributes eye trackers for its clients.e(ye)BRAIN’s range of products include Eye Brain T1 and T2. The T1 enables its users to record eye movements. T2 uses algorithms to enable its users to record eye and head movements. The recorded movements will be analyzed by a software called MeyeEval.The company offers advisory, paradigm development, formation, and support services to its clients.e(ye)BRAIN was founded in 2008 by Serge Kinkingnehun and is based in France. | $1.8M | Series A | Nov 18, 2009 |  |

10 of 19 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 3 deals together
- [AVP](https://shizune.co/investors/profile/axa-strategic-ventures) — VC Fund, 2 deals together
- [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital) — VC Fund, 2 deals together
- [Amorçage Rhône Alpes](https://shizune.co/investors/profile/amorage-rhne-alpes) — VC Fund, 1 deal together
- [Ardian](https://shizune.co/investors/profile/ardian) — VC Fund, 1 deal together
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 1 deal together

## About Karista

VC Fund · Paris, France

Karista is an early-stage venture capital firm created in 2001. We funded 90+ companies over the past two decades and support tomorrow’s game changers in the field of Health, Digital, Tech, and NewSpace. We have always worked to provide more than cash and partnered with entrepreneurs whom we share a common vision with.

5 contacts available at Karista.

| Name | Title | Profile |
| --- | --- | --- |
| Agathe Testu | Secretary General - RCCI | https://shizune.co/investors/profile/agathe-testu |
| Baudouin Hue | Partner | https://shizune.co/investors/profile/baudouin-hue |
| Benjamin Zerbib | Investment Director | https://shizune.co/investors/profile/benjamin-zerbib |
| Catherine Boule | Managing Partner | https://shizune.co/investors/profile/catherine-boule |
| Elodie Feraille | Management Assistant | https://shizune.co/investors/profile/elodie-feraille |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Catherine Boule invest in?

Catherine Boule invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Catherine Boule last invest?

The most recent investment recorded for Catherine Boule closed in Sep 2022. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co